Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLD-103
- Development stage
- Preclinical
- Lead developer
- Pelemed
- Modality
- Small Molecules
01
Overview
PLD-103 is a discovery-stage small molecule inhibitor being developed by Pelemed to target the YAP-TEAD transcriptional program. The interaction between Yes-associated protein (YAP) and Transcriptional Enhanced Associate Domain (TEAD) transcription factors is the terminal step of the Hippo signaling pathway, which plays a critical role in regulating organ size, cell proliferation, and survival. In many cancers, this pathway is dysregulated, leading to constitutive YAP-TEAD activity that drives tumor growth, metastasis, and resistance to therapy. PLD-103 is designed to disrupt this transcriptional complex, offering a potential therapeutic approach for a variety of YAP-TEAD-dependent malignancies.
Beyond the preview
Go deeper on PLD-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLD-103.